Yüklüyor......

Harnessing immune responses in the tumor microenvironment: All signals needed

An agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing immunotherapies in comb...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Le, Dung T., Jaffee, Elizabeth M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3839670/
https://ncbi.nlm.nih.gov/pubmed/24097857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2424
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!